Live news related to NANOBIOTIX stock (FR0011341205): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
Nanobiotix announced on Sunday the presentation of data from the first part of the phase 2 CONVERGE clinical study, conducted in partnership with John…
French biotech Nanobiotix experiences a setback after a week of euphoria. Its shares fell by 3.72% to €44.46 during mid-session Friday, following a hi…
Nanobiotix stock continues its climb this Thursday, May 14. The French biotech's share reached a new all-time high of €45.86 during the session, surpa…
On Wednesday, May 13th, Nanobiotix stock continues its spectacular trajectory, gaining 3.38% to reach €41.62 in early afternoon trading. The stock ran…
Nanobiotix stock reached a new all-time high of €44.44 during the session this Tuesday, May 12, surpassing the previous peak of €44.18. The stock is t…
The French biotech company reaches a new all-time high of €41.52 during the session, surpassing the previous peak of €40.52. The stock is trading at €…
The French biotech company experienced another euphoric session this Thursday, May 7. The stock reached an all-time high of €38.40 intraday, before se…
The stock of the French biotech company sharply accelerates at midday, driven by a very dynamic Parisian market and the response to the amendment appr…
The stock of the French biotech firm rallies during Tuesday's session, following the announcement of the Phase 3 NANORAY-312 trial. The share price is…
Nanobiotix announced on Monday the FDA's acceptance of an amendment to the global Phase 3 NANORAY-312 study protocol on head and neck cancer. This ame…
